demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 hospitalized
COVID-19 severe or critically
janus kinase (JAK) inhibitor
baricitinib COV-BARRIER ...
ruxolitinib Cao DEVENT
TD-0903
TD-0903 10mg Singh ...
TD-0903 1mg Singh ...
TD-0903 3mg Singh ...

5 studies excluded by filtering options 1

6141 Rodriguez-Garcia, 2020 1100not a RCTrisk of bias not avaialble
6415 Cantini, 2020 2310excludednot a RCTrisk of bias not avaialble
6430 Cantini, 2020 1134not a RCThigh risk of bias
6490 Kaplanski, 2020 0300selection pending
9239 Tziolos, 2021 1130not a RCTrisk of bias not avaialble